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Aim: To evaluate the impact of health-related quality of life (HRQoL) enfuvirtide-based 
(ENF-based) salvage regimens of treatment-experienced HIV patients, in an observational 
multicenter cohort study.
Methods: HRQoL was measured in a cohort of 16 patients over a 6-month follow-up using 
2 instruments: the ISSQoL (Istituto Superiore di Sanità Quality of Life), a recently validated 
HIV-speciﬁ  c questionnaire; the EQ-5D (EuroQol), a generic widely used instrument. ENF was 
given at standard dosage along with an optimized background regimen.
Results: Most of HRQoL dimensions showed improvement in ENF-treated patients at the 
post-baseline time points. Social functioning was the only dimension showing a negative effect. 
Monthly care costs of antiretroviral drugs for HIV patients taking ENF plus an optimized back-
ground regimen were approximately  2,348 per patient-month (range  382– 2,940).
Conclusion: Our results show that the addition of ENF to an optimized background salvage-
HAART may positively affect HRQoL not only in clinical trials but also in a sample population 
of patients used in a routine clinical practice.
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Introduction
Enfuvirtide (ENF) is the ﬁ  rst approved HIV-entry inhibitor, available for clinical 
use, highly effective as part of a regimen for treatment-experienced patients showing 
extensive multiclass drug re  sistance. This drug is also the ﬁ  rst and only antiretroviral 
that requires self-administered subcutaneous injections.
Two large multicenter clinical trials (Lalezari et al 2003; Lazzarin et al 2003) 
demonstrated the efﬁ  cacy of ENF-containing regimens on immunologic and virologic 
responses. ENF-treated patients also experienced signiﬁ  cant improvements in several 
dimensions of health-related quality of life (HRQoL).
These latter ﬁ  ndings support the idea that patient-reported outcomes (PROs), such 
as HRQoL, nowadays play a central role in measuring patient’s health status. Although 
the improvement of quality of life is one of the primary goals of antiretroviral therapy 
(Guidelines 2007), available data on HIV infection mostly refer to medical aspects, 
only providing an incomplete assessment of the composite effects of treatment. They 
lack information that comes directly from the patient. Little patient-centered data 
have been collected up to now, mostly from clinical trials (Cohen et al 2004; Shalit 
et al 2007).
The principal aim of this study was to provide information on HRQoL in ENF-treated 
subjects in a routine clinical practice.Biologics: Targets & Therapy 2008:2(3) 578
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Methods
Study treatments and patients
T20QoL was an observational, longitudinal study to assess 
the impact of  ENF on HRQoL in HIV-positive patients. Data 
on 16 subjects were collected over a 6-month period. Enrolled 
HIV-infected patients met the following requirements: 
18 years of age or older; patients had to be antiretroviral 
drug-experienced and fusion inhibitor-naïve; an indication 
for the initiation of therapy including ENF. Exclusion criteria 
included pregnancy and patients unable to read or complete 
the questionnaires. ENF was given at standard dosage (90 mg 
subcutaneous injection, twice a day), along with a selected 
optimized background regimen. Three large Italian clinical 
centres (IRCCS L. Spallanzani, Ospedale L. Sacco, Spedali 
Civili di Brescia) participated in the study. Each center taking 
part in the study obtained an ethics committee approval and 
participants provided a written informed consent.
Data collection
Baseline information included demographic data (gender, 
age, route of transmission, and HIV disease duration). 
Clinical information included HIV disease status (CDC dis-
ease stage), HIV RNA viral load (VL) and CD4+ cell count. 
HRQoL measurement data, injection site reactions, adverse 
events, CD4 count, and VL were collected at baseline and 
2 follow-up visits at months 3 and 6.
HRQoL measurement
To evaluate HRQoL, the EQ-5D (EuroQoL) and the ISSQoL 
(Istituto Superiore di Sanità Quality of Life) self-administered 
instruments were adopted.
The ISSQoL is a recently validated HRQoL speciﬁ  c 
instrument carefully designed for people living with HIV 
in the HAART era (Bucciardini et al 2006). This instrument 
includes two sections: HRQoL Core Evaluation Form and 
Additional Important Areas for HRQoL. The HRQoL Core 
Evaluation Form includes 9 Core domains: satisfaction 
with quality of life (SQL), physical well-being (PW), role 
well-being (RW), depression and anxiety (DA), energy and 
vitality (EV), health distress (HD), cognitive functioning 
(CF), social functioning (SF), and sexual life (SL). The 
Additional Important Areas for HRQoL include 6 domains: 
social support (SS), interaction with medical staff (MS), 
treatment impact (TR), body changes (BC), life planning 
(LP), motherhood/fatherhood (MF). For this study only the 
Core Evaluation Form was used. The ISSQoL domains were 
scored on a 0–100 scale, with 0 indicating ‘poorest’ health 
and 100 indicating ‘best’ health.
The EQ-5D (Brooks 1996) is a widely used generic 
questionnaire consisting of 5 domains (mobility, self care, 
usual activities, pain/discomfort and anxiety/depression) 
and 3 levels with 1 indicating “no problem”, 2 indicating 
“some or moderate problem” and 3 indicating “extreme 
problems/impossible to do”.
Cost of ARV therapy
In this study, the only direct costs referred to anti-HIV drugs 
used as part of salvage regimens were considered. Medical 
costs were quantiﬁ  ed considering National Health Service. 
Cost estimation was based on data provided by hospital 
pharmacies, also taking into account discounts offered by 
pharmaceutical companies to the hospitals.
Calculations were performed on daily costs of each drug, 
on the basis of standard dosages, the number of patient pre-
scribed medication, and the therapy duration in days. Costs 
obtained were expressed in terms of “patient-month”.
Statistical analysis
Baseline characteristics (demographic, clinical, and HRQoL) 
were summarized by descriptive statistics. To estimate the 
magnitude of HRQoL (ISSQoL and EQ-5D) changes over 
time the “effect size” was used (Cohen 1977; Guyatt et al 
1987; Kazis et al 1989). Effect size was calculated as the ratio 
of the difference between post-baseline and baseline mean 
scores, divided by baseline standard deviation.
Injection-site reactions were assessed according to an 
overall grade that was based on the level of pain and dis-
comfort. Baseline mean changes were examined at 3 and 
6 months for VL and CD4+ cell counts.
Statistical calculations were performed using SAS statis-
tical package, version 8.2 (SAS Institute, Inc., Cary, North 
Carolina, USA).
Results
Baseline characteristics of the study 
population
In this study 88% of the participants were male; 44% were 
heterosexual. Mean age was 44. The subjects were HIV-
infected for a mean of 13 years and 44% of them had a his-
tory of an AIDS-deﬁ  ning event. At baseline, mean HIV viral 
load was 4.0 log and mean CD4 cell count was 190 cells/μL 
(Table 1). The optimized background regimen associated with 
ENF included a mean of 4 antiretroviral drugs (range 2–5).
Mean baseline ISSQoL domains ranged from 45 to 76. 
For EQ-5D proﬁ  le, 60% and 80% of the participants reported 
“no problems”, respectively, for mobility and self-care. Biologics: Targets & Therapy 2008:2(3) 579
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Approximately half of these (53%) had “some problems” 
in performing usual activities and in the pain/discomfort. 
“Extreme problems” in anxiety/depression dimension were 
reported in 27% of the participants.
HRQoL measurement
ISSQoL
Changes over time in ISSQoL dimension scores, presented 
as mean QoL scores, and as effect sizes after 3 and 6 months 
of treatment are shown in Table 2 and Table 3.
A positive “small” effect size for physical well-being, 
role well-being, and energy/vitality both at 3 and 6 months 
was observed, and for satisfaction with quality of life and 
health distress after 6 months was observed. A negative 
“small” effect size for cognitive functioning after 3 months 
of follow-up was observed.
A “moderate” negative effect size for the social 
functioning of –0.6 and –0.3 after 3 and 6 months respectively 
was observed. No signiﬁ  cant change during the follow-up for 
the anxiety/depression and sexual life was reported.
EQ-5D
On average, the EQ-5D proﬁ  le of the enrolled sample 
subjects had improved over time (Table 2). The effect sizes 
were for all dimensions, at the least “small” (0.20–0.40) in 
both 3 and 6 months; for the Usual Activities the effect size 
was moderate (0.50) (Table 3).
Injection-site reactions (ISRs)
After 3 and 6 months of treatment, 50% and 64% of partici-
pants reported grade 1 pain due to ISRs, respectively.
Grade 1 Erythema was observed in 50% of participants 
after 3 months as well as after 6 months; 1 subject reported 
grade 4 erythema after 3 months and 1 reported grade 2 after 
6 months.
In total, after 3 and 6 months, 71% of participants reported 
at least one IRS of any grade. After 3 and 6 months 36% and 
50% of participants, respectively, reported symptoms of pain 
and erythema (data not shown).
After 6 months of follow-up no adverse events in our 
group of participants were observed.
Clinical, virological,
and immunological follow-up
Over a 6-month period no change of clinical status was 
observed (data not shown). During follow-up, an improve-
ment of both immunological and virological parameters was 
observed (data not shown). The mean increase in CD4+ cell 
count was 108 ± 76 cells/μL (range, –43 to 223) after 3 months, 
and 114 ± 101 cells/μL (range, –18 to 354) after 6 months of 
therapy. Compared with baseline values, the mean decrease 
in plasma HIV RNA was 1.5 ± 1.0 log10 copies/mL after 3 
months, and 1.4 ± 1.2 log10 copies/mL after 6 months.
Use of resources
Monthly care costs of antiretroviral drugs for HIV 
patients taking ENF plus an optimized background regi-
men was approximately  2,348 per patient-month (range 
382– 2,940).
Discussion
In the current study was investigated the HRQoL in subjects 
receiving ENF-based salvage HAART in an unselected 
population of heavily pre-treated HIV-infected patients in 
Italian clinical centres.
We found that using Cohen’s guidelines for the magnitude 
of the effect size, the impact of the ENF on health status was 
clinically meaningful (at least small) for most of dimensions at 
3 and 6 months in both ISSQoL and EQ-5D questionnaires.
Table 1 Population characteristics
Patients
N°, randomized 16
Gender
  Female: n (%) 2 (12.5)
  Male: n (%) 14 (87.5)
Age (years)
 mean  ± SD (n, range) 44.3 ± 8.0 (16, 34–63)
 median 43.0
Transmission route: n (%)
 Homo/bisexual 4  (25.0)
  IV drug use 4 (25.0)
 Heterosexual 7  (43.8)
 Blood 1  (  6.3)
CD4+/mm3
 mean  ± SD (n, range) 190 ± 124 (16, 6–405)
 median 158
HIV-RNA cp/mL (log10)
 mean  ± SD (n, range) 4.0 ± 1.0 (16, 1.7–5.5)
 median 4.2
Clinical status: n (%)
 CDC  A 2  (12.5)
  CDC B 7 (43.8)
  CDC C 7 (43.8)
Time from HIV diagnosis (years)
 mean  ± SD (n, range) 13.4 ± 4.3 (16, 7–21)
 median 13.0Biologics: Targets & Therapy 2008:2(3) 580
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A signiﬁ  cant negative effect was only observed in the 
social functioning dimension. However, we found signiﬁ  cant 
improvements in CD4+ cell count and reductions in plasma 
HIV-RNA.
To date, little information exists on the relationships 
between HRQoL and ENF-based salvage HAART. In a 
previous study, Cohen et al (2005) assessed the impact of 
ENF on HRQoL among patients who experienced failure of 
HAART, enrolled in two phase 3 trials comparing ENF plus 
background therapy with background therapy alone. Most of 
HRQoL dimensions (MOS-HIV) showed an improvement in 
the ENF arm at all post-baseline time points. Social functioning 
was the only dimension showing a negative effect.
More recently, Shalit et al (2007) examined baseline 
predictors of life quality improvements in a prospective 
open-label study of patients treated with ENF in combination 
with other antiretrovirals. The results showed signiﬁ  cant 
improvements in most of the MOS-HIV domain scores: 
physical function, mental health, general health percep-
tion, pain, energy, quality of life, cognitive function, health 
distress and health transition. Social functioning and role 
functioning, were the only domains which did not have any 
signiﬁ  cant improvements.
A decrease in the social functioning score observed in 
our study is possibly related to the inconvenience mode 
of ENF administration as well as to ISRs. Both these 
Table 2 Quality of life scores during the follow-up
ISSQOL Baseline 3 months 6 months
QoL core evaluation form
mean ± SD (n, range)
Satisfaction with quality of life 45 ± 21 (14, 17−75) 52 ± 19 (11, 25−83) 58 ± 11 (11, 42−75)
Physical well-being 63 ± 30 (15, 21−100) 75 ± 22 (13, 33−100) 80 ± 16 (11, 50−100)
Role well-being 62 ± 38 (14, 0−100) 79 ± 32 (12, 0−100) 77 ± 24 (11, 38−100)
Social functioning 76 ± 25 (14, 38−100) 61 ± 38 (12, 0−100) 67 ± 33 (11, 0−100)
Anxiety/Depression 64 ± 26 (15, 25−100) 68 ± 27 (12, 21−100) 68 ± 23 (12, 32−96)
Energy/Vitality 50 ± 29 (14, 13−100) 60 ± 29 (11, 6−94) 64 ± 20 (10, 38−94)
Health Distress 62 ± 31 (15, 13−100) 61 ± 31 (12, 13−100) 68 ± 24 (12, 25−100)
Cognitive functioning 66 ± 24 (15, 19−100) 63 ± 32 (13, 13−100) 69 ± 26 (12, 25−100)
Sexual life 45 ± 28 (15, 0−85) 42 ± 32 (12, 0−90) 41 ± 29 (12, 0−80)
EQ-5D dimensions
Mobility: mean ± SD (n, range) 1.5 ± 0.6 (15, 1–3) 1.2 ± 0.4 (13, 1−2) 1.1 ± 0.3 (11, 1−2)
  no problem (%) 60 85 91
  some problem (%) 33 15 9
  extreme problem (%) 7 −−
Self-care: mean ± SD (n, range) 1.2 ± 0.4 (15, –2) 1.1 ± 0.3 (13, 1−2) 1.0 ± 0.0 (11, 1−1)
  no problem (%) 80 92 100
  some problem (%) 20 8 −
  extreme problem /%) −−−
Usual activities: mean ± SD (n, range) 1.7 ± 0.6 (14, 1−3) 1.3 ± 0.5 (12, 1−2) 1.3 ± 0.5 (11, 1−2)
  no problem (%) 33 67 75
  some problem (%) 53 33 25
  extreme problem (%) 7 −−
Pain/Discomfort: mean ± SD (n, range) 1.7 ± 0.6 (15, 1−3) 1.4 ± 0.5 (13, 1−2) 1.4 ± 0.5 (11, 1−2)
  no problem (%) 40 62 64
  some problem (%) 53 38 36
  extreme problem (%) 7 −−
Anxiety/Depression mean ± SD (n, range) 1.9 ± 0.8 (15, 1−3) 1.6 ± 0.7 (13, 1−3) 1.4 ± 0.5 (12, 1−2)
  no problem (%) 40 46 58
  some problem (%) 33 46 42
  extreme problem (%) 27 8 −Biologics: Targets & Therapy 2008:2(3) 581
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possibilities were highlighted by Cohen et al (2004) in 
their study. 
For the injection site reaction, observed at 3 and 6 months, 
our ﬁ  ndings are consistent with previous studies, although 
the percentages reported by Cohen et al and Shalit et al were 
higher.
In this study, improvements related to mobility and usual 
activities dimensions were noteworthy results, showing the 
recovered ability of the subject to act normally during the 
daily routine.
Further improvements were with the anxiety/depression 
and the satisfaction with quality of life dimension scores. An 
explanation of this result could be the participants’ awareness 
of the availability of an effective therapeutic option. This 
could possibly induce a more positive future outlook, thus 
minimizing the potential for anxiety and depression and thus 
improving the quality of life.
Further information on costs of ENF-based regimens 
was also provided in our study (Hornberger et al 2005, 
2006; Sax et al 2005). Our results are consistent with data 
reported in literature (Shackman et al 2006), in which the 
cost of ENF-based regimens was US $3,770 ( 2,421) per 
month. The cost of salvage therapy without ENF of US $1,970 
( 1,265) per month was also reported (Shackman et al 2006). 
These data suggest that ENF introduction into HAART leads 
to a signiﬁ  cant increase in drug expenditure.
Our study had some limitations. The number of subjects 
studied was very small and the observed time of follow-up 
was short. Therefore, our observations should be elaborated 
in larger and longer clinical-based observational cohorts.
In summary, our results indicate that the addition of ENF 
to an optimized background salvage-HAART may positively 
affect HRQoL in a population sample of subjects seen in a 
routine clinical practice.
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Table 3 Effect size of changes on ISSQoL and EQ-5D dimensions
ISSQOL Effect size 
after 3 months 
(*)
Effect size 
after 6 
months (*)
QoL core evaluation 
form
Satisfaction with quality 
of life
0.1 (1.5/19.4) 0.4 (9.1/21.3)
Physical well-being 0.2 (5.9/26.6) 0.3 (6.9/25.3)
Role well-being 0.2 (7.3/30.7) 0.3 (8.0/30.8)
Social functioning –0.6 (–14.6/25.3) –0.3 (–8.0/26.2)
Anxiety/Depression 0.1 (2.1/28.8) 0 (1.0/28.2)
Energy/Vitality 0.2 (6.8/32.3) 0.3 (9.4/33.0)
Health distress 0 (0.0/34.5) 0.2 (5.7/33.7)
Cognitive functioning –0.2 (–4.8/25.4) 0.0 (–1.0/24.7)
Sexual life –0.1 (–1.9/28.6) 0.1 (–4.0/28.0)
EQ-5D Dimensions
Mobility –0.3 (–0.23/0.7) –0.4 (–0.27/0.7)
Self-care –0.2 (–0.07/0.4) –0.3 (–0.09/0.3)
Usual Activities –0.5 (–0.25/0.5) –0.5 (–0.27/0.5)
Pain/Discomfort –0.3 (–0.23/0.7) –0.3 (–0.18/0.7)
Anxiety/Depression –0.3 (–0.23/0.9) –0.4 (–0.33/0.9)
(*) Between breaks: difference post baseline and baseline mean/SD.